ARA-290 16mg – Targeted Peptide for Pain Relief, Immune Support & Tissue Repair

ARA-290, also known as Cibinetide, is a cutting-edge research peptide derived from erythropoietin (EPO) – a naturally occurring protein in the body. Unlike traditional EPO, ARA-290 does not increase red blood cell production, but instead focuses on promoting tissue protection, reducing inflammation, supporting vascular health, and easing nerve pain, especially in chronic conditions like diabetes and autoimmune diseases.

What is ARA-290?

ARA-290 is a synthetic peptide modeled after a specific region of EPO. While EPO is best known for stimulating red blood cells, it also has powerful protective effects on nerves, blood vessels, and tissues. ARA-290 isolates these protective benefits—without triggering the hematopoietic (blood cell-producing) side effects.

Early clinical research and ongoing trials show promise for ARA-290 in managing conditions like:

• Diabetic neuropathy

• Autoimmune sarcoidosis

• Systemic lupus erythematosus (SLE)

• Impaired wound healing

• Inflammatory bowel diseases like Crohn’s and ulcerative colitis

How ARA-290 Works

ARA-290 works by activating the innate repair receptor (IRR) and the tissue protective receptor (TPR)—special pathways in the body that help repair damaged tissue and regulate immune responses. These actions lead to:

• Reduced inflammation

• Faster tissue recovery

• Lowered neuropathic pain

• Enhanced survival of transplanted cells (such as insulin-producing islets)

Key Benefits Observed in Research

✅ Supports Blood Vessel Health

ARA-290 helps repair damaged blood vessels and encourages the growth and migration of endothelial cells, which are crucial for circulation and healing. This may have major implications for vision loss, wound healing, and cardiovascular function.

✅ Reduces Inflammation & Protects Tissues

By calming pro-inflammatory cytokines like IL-6 and TNF-alpha, ARA-290 creates a more balanced immune response. This is especially valuable in autoimmune diseases and transplant-related inflammation.

✅ Modulates the Immune System

ARA-290’s immune-modulating properties make it a potential candidate for conditions like colitis and lupus. It works by fine-tuning the immune response—promoting healing while avoiding immune overactivation that causes long-term damage.

✅ Eases Neuropathic Pain

ARA-290 has shown effectiveness in reducing pain caused by nerve damage, especially in small fiber neuropathy linked to diabetes and sarcoidosis. It also appears to affect the TRPV1 channel—known for its role in “burning” nerve pain sensations—making it a potential breakthrough for hard-to-treat pain.

ARA-290 Quick Facts

• Synonyms: Cibinetide, PH-BSP

• Sequence: ZEOLERALNSS

• Molecular Weight: 1257.3 g/mol

• Formula: C₅₆H₈₃N₁₇O₁₇

• CAS Number: 1208243-50-8

• PubChem CID: 91810664

Current Research & Regulatory Status

ARA-290 is currently in Phase II and III clinical trials for conditions like diabetic neuropathy and painful sarcoid neuropathy. It has received Orphan Drug Designation by the FDA, highlighting its potential as a treatment for rare and underserved conditions.

Its minimal side effects and strong tissue-targeting profile have made it a peptide of high interest in both academic and clinical research environments.

Intended Use

ARA-290 is available strictly for scientific and educational research purposes. It is not approved for human or veterinary use. Only licensed professionals should handle this peptide under proper laboratory conditions.